Bone marrow cells obtained from 14 patients with light chain amyloid (AL) deposition were examined by biosynthetic labeling techniques. These analyses identified free monoclonal light chain (L-chain) synthesis even in those patients whose serum or urine contained no M protein or free L-chains or only an intact M protein. The experiments also identified a subset of patients whose plasma cells synthesized polypeptides bearing constant region antigenic determinants that migrated more rapidly than intact L-chains on polyacrylamide gels. Since most AL fibrils contain L-chain fragments rather than intact L-chains, these studies suggested that the genesis of the fibril components may reflect aberrant synthesis, proteolytic processing, or both. We also noted that in some individuals the pattern of Ig synthesis normalized after several courses of cytotoxic therapy. Thus, we could use bone marrow Ig synthesis as a sensitive biochemical parameter for monitoring therapy. Finally, the presence of aberrant synthetic products in these clones raised questions about their origin with respect to the normal processes of transcription, translation, and posttranslational modification in Ig-producing cells.
Introduction
It has been known for several years that the major fibrillar protein found deposited in the tissues of individuals with primary amyloidosis and the amyloidosis associated with multiple myeloma, i.e., light chain (AL)' amyloidosis, is related to a monoclonal light chain (L-chain) (1) . In most patients a monoclonal M protein or free L-chain has been found in the serum or urine (2) . In several cases the amino acid sequences of the fibril and the monoclonal urine or serum protein have been determined and found to be identical (3, 4) . Many fibril proteins have been studied in detail and reported (3) (4) (5) (6) (7) (8) (9) (10) . In only 5 of 17 cases have the deposits contained intact L-chains. In two, L-chain monomers were the only component ofthe extracted fibrils. In the majority, the deposits have contained primarily fragments, all of which have normal L-chain variable (V region) amino-termini. Three A portion of this work was presented at the Fourth International Conference on Amyloidosis, Harriman, New York, November 1984.
Receivedfor publication 5 August 1985 and in revisedform 9 May 1986. ofthese also contained intact L-chains. In a few cases the reduced peptides are larger than normal L-chains. The biogenesis of the short fragments could represent proteolysis, aberrant synthesis, or a combination of both. The longer molecules may represent distorted synthesis or polymerization via nondisulfide mechanisms, taking place either in vivo or during fibril preparation.
These observations pose the following question. Is deposition a function of the synthesis ofintact or aberrant proteins that are susceptible to tissue deposition per se, or does specific proteolysis of any L-chain render it insoluble and liable to pathologic tissue deposition? If synthesis of abnormal Ig subunits is critical, then the presence of the deposition disease will identify individuals in whom detailed analysis of synthesis may be useful in further elucidating the mechanisms regulating the production of Ig polypeptides.
The present studies were designed to examine Ig biosynthesis in patients with AL disease to determine ifthe deposited proteins could be primary synthetic fragments. We have also attempted to use the same analytic techniques as clinical tools in the evaluation of patients with this disorder, particularly those patients whose serum and urine do not contain free monoclonal L-chains.
Methods
All patients had biopsy-proven amyloidosis. Sera from all patients were examined by cellulose acetate electrophoresis and immunoelectrophoresis with a variety of monospecific, commercially available antisera with wellcharacterized heavy or L-chain specificity (1 1). Urines were concentrated up to 400-fold if no evidence of a monoclonal protein was noted at a 25-fold concentration. Concentration was carried out by either Sephadex absorption or the use of minicon membranes (Amicon Corp, Danvers, MA) (12) .
Biosynthetic studies were performed using bone marrow cells obtained at the time of diagnostic aspiration and biopsy. Marrow was aspirated into a heparinized syringe and transferred to a sterile polypropylene tube containing 25 ml of Eagle's minimal essential medium lacking valine, leucine, and methionine, but containing 5-10 U/ml of heparin without preservatives [(-) medium]. The cells were centrifuged at room temperature and the buffy coat removed. The buffy coat was washed twice more in (-) medium, resuspended in 5 ml, and the live nucleated cells enumerated after erythrocin B staining ( 13) . The cell concentration was adjusted with (-) medium to between 3 and 5 X 106 cells/ml. 100 ACi each of [3H]valine and leucine and 100 gCi of [35S]methionine were neutralized with isotonic-buffered saline and added to each milliliter of cell suspension at time 0. The number and spacing of the time points were determined by the number of cells available. The percentage of plasma cells in the marrow was determined by examination ofthe smear by the attending hematologist. In some cases, where therapy was instituted, repeat marrow examinations were performed at intervals deemed appropriate by the patients' attending physicians.
Analyses of the synthesized and secreted material were carried out after separation ofthe cells and supernatant medium. At each time point
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J. Buxbaum the sample was made 0.1 M with respect to iodoacetate in order to block free sulfhydryl (SH) groups and prevent polymerization by disulfide interchange, and chilled. The cells were centrifuged in the cold and the supernatant removed and saved for analysis as secreted material. The cell pellet was suspended in 9 ml ice-cold distilled water for I min in order to lyse residual red cells, then brought to isotonicity by the addition of I ml of 10 X buffered saline. The cells were centrifuged in the cold (10 min). The supernatant was removed and the pellet washed again with cold medium. The final cell pellet was suspended in I ml hypotonic buffer per 5 X 106 cells and 0.1 vol 5% Nonidet P-40 (NP-40) added (14) . The tube containing the cells was placed in an ice bucket for 30 min then spun at 100,000 g in an ultracentrifuge (L265B; Beckman Instruments, Inc., Fullerton, CA) using a 50 rotor. The resultant supernatant fluid was treated as cytoplasm. Trichloroacetic acid precipitation of I0-,gl portions of cytoplasm and secretions were performed to establish the linearity of incorporation of radioactive precursors into total cell protein and secretions and to determine the relative amount of protein synthetic activity by the marrow cell population (15) . Immunologic precipitations of radioactive cytoplasm and secretions were carried out with a variety ofcommercially available polyclonal and monoclonal antisera specific for particular Ig chains. Some antisera were prepared in our own laboratory. Each ofthe antisera was titrated against a 1/50 dilution of a normal standard reference serum, which was then used as a carrier in the experimental precipitations. A calculated twofold excess of antibody to carrier was utilized in all precipitations. When monoclonal antibodies were used, all samples were precleared with staphylococcal protein A beads before the addition of the monoclonal antibody and a second portion of protein A-containing beads adequate to bind the added antibody (16) .
Precipitates were washed with 0.5 M NaCI and 0.05% NP-40 three times, then vigorously dispersed in 50 ul 2% sodium dodecyl sulfate (SDS) and 0.5% NP-40, and then placed in a boiling water bath for I min. Staphylococcal protein A-bound antigens were released by boiling the beads in 2% SDS and 0.5% NP-40 and separating the solubilized bound material from the beads by centrifugation. The specifically precipitated radioactivity in the precipitates was determined by liquid scintillation counting. The amount of immunologically precipitated radioactive protein determined how much ofeach precipitate would be reduced and alkylated (10 mM dithiothreitol and 0.1 M iodoacetamide) before gel analysis.
Unreduced samples were generally electrophoresed on 7.5-10% polyacrylamide gels containing 0.1% SDS. Reduced samples were run on 17.5% gels. We noted that in some cases the reduced and alkylated L-chain monomers migrated more slowly than naturally occurring unreduced L-chains. Gels were processed using either ENHANCE or Enlighten (New England Nuclear, Boston, MA), dried on filter paper in a gel-drying apparatus, and exposed for autoradiography (17) .
Known marker proteins were electrophoresed on each gel. A representative analysis of the proteins synthesized by an individual with polyclonal hyperglobulinemia is shown in Fig. 1 .
The major molecule synthesized was IgG, which was precipitable with both anti-kappa and anti-lambda sera (Fig. 1 A) . IgM was also precipitable with both antisera and found at the top ofthe gel (Fig. I B) . Fig. 1 , lane 1 shows that the anti-kappa serum also precipitated molecules that migrated as L-chain monomer and dimer ( Fig. 1 C and D) . A faint band ( Fig. 1 E) corresponding to the position of lambda dimer could also be discerned (Fig. 1, lane 3) . Reduction and alkylation of both the kappa and lambda precipitates released heavy chains (H-chains) (Fig. 1 Equal amounts of lysates of cells from a patient with polyclonal hyperglobulinemia that had been incubated with radioactive amino acids, as described in Methods, were precipitated with antisera specific for kappa (lanes I and 2) or lambda (lanes 3 and 4) L-chains. The immune precipitates were dissolved in running buffer and electrophoresed on 0.1% SDS-containing polyacrylamide gels with (lanes 2 and 4) or without reduction.
(A) Comigrating with the murine H2L2 marker, this band is precipitable with both anti-kappa and anti-lambda serum. It represents the normal population of polyclonal IgG molecules synthesized by the marrow. (B) Trapped at the top of the running gel in lanes 1 and 3, B represents IgM. Reduction and alkylation of the precipitates yields two bands in the heavy chain region (M and Sy) with both antisera and a single band in each L-chain region. In lane 2 the reduced and alkylated kappa band comigrates with the free excess kappa chains synthesized by the marrow cells (C). A small amount of unreduced kappa dimer is also seen (D). Band E, barely seen in lane 3, represents unreduced lambda dimers. The L-chain released by reduction and alkylation of the lambda precipitate migrates more slowly than the similarly treated kappa chain (35). In lane I an additional band, precipitable with both the kappa and lambda antisera and migrating with a mobility corresponding to a protein of -75,000 mol wt probably represents a heavy-light heterodimer. In other experiments not shown, it is also precipitable with an anti-gamma serum. The autoradiograms were overexposed in order to visualize molecules seen in trace amounts. Using this procedure, no molecules smaller than L-chains were seen in this or other similar experiments.
amyloid, not myeloma kidney. Two patients had myeloma with amyloid while one had macroglobulinemia.
All patients studied synthesized excess free Ig light chains (Table II) . 10 patients produced lambda and 4 produced kappa. Monoclonal H2L2 production was shown in patients 7 and 9. Polyclonal H2L2 production by normal bone marrow cells was also detected in most patients but not included in the table.
All patients except one (patient 10) had L-chain dimers in both cytoplasm and secretions (Table II) . Among lambda producers, dimers were the dominant molecular species secreted during the 4-h incubation period. In cells secreting kappa chains, the monomer was always the prevalent form both intra-and extracellularly. Kinetic experiments indicated that the dimeri- Five of the patients synthesized molecules that were precipitable with anti-L-chain sera but were smaller in size than the intact L-chains (Figs. 2 and 3). The estimated molecular weights (mol wt) ofthe reduced fragments, as determined by the relative electrophoretic mobilities on these gels, ranged from 12,500 to 27,000.
In patient 1 ( Fig. 2) , after 4 h of incubation the secreted material contained anti-lambda-precipitable material of24,500 (B) and 49,000 mol wt (A) representing L-chain monomer and dimer, respectively. In the cytoplasm, additional bands of23,000, 16,000, and <12,000 mol wt were also noted (Fig. 2, lane 2) . The latter two molecules were also precipitable with a polyclonal serum directed against #2 microglobulin but not with polyclonal anti-kappa serum (Fig. 2, lanes 3 and 4) . Monoclonal antilambda serum precipitated only the 49,000, 24,500, and 23,000-mol-wt species. Hence it appears that the only apparent fiagment (XF) seen in this patient was -6% smaller than the intact Lchain. It did not appear to dimerize and was not found in significant quantities outside the cell during the observed incubation period.
Labeled cytoplasm and secretions from patient 6 contained three major anti-kappa-precipitable molecules, H2K2, K2, and K, and a kappa protein of 27,000 mol wt (CF). Fig. 3 , lane I shows that the dominant anti-kappa-precipitable cytoplasmic molecule is the kappa monomer (A). A smaller amount ofdimer is also seen (Fig. 3 B) as is a faint band migrating more rapidly than the intact L-chain (C). In the secreted material the same bands are noted (Fig. 3, lane 3) as is a small amount of H2L2. Anti-lambda precipitates (Fig. 3, lanes 2 and 4) show only barely detectable H2L2. The positions ofthe molecular weight markers are noted. Similar findings were noted in patient 13 (not shown). The findings in patient 14 have been reported previously (18) .
Lambda tetramers were found both intra-and extracellularly.
Reduction of the anti-lambda precipitates released a 10,000-12,500-mol-wt fiagment not seen in the unreduced preparations.
Patient 11 had the most complex biosynthetic profile in the entire group of patients (Fig. 4) . After 10 min of incubation the major cytoplasmic molecule had a relative molecular mass of 47,000 and represents X2 (Fig. 4 A) . A smaller amount oflambda monomer (Fig. 4 B) is seen. At later times a 15,000-mol-wt anti-lambda-precipitable polypeptide is also found (Fig. 4 C) .
In samples prepared from the 10, 30, 45, and 60-min cytoplasms an additional band is noted (Fig. 4 D) with an estimated molecular weight of 42,000. It appears to represent a monomerfragment heterodimer (XXF). It is found in the secretions and seems to diminish in the cytoplasm with kinetics similar to the X2 dimer ( Fig. 5 A and B) . At 60 min of continuous labeling the dimer represented 53% ofthe lambda-precipitable material, the monomer 25%, the fragment 12%, and the fragment dimer 10%. After 4 h, the monomer comprises 45%, the dimer 30%, the fragment 24%, and the fragment dimer <1%. Since the experiment was not carried out with a cold amino acid chase it was difficult to establish precursor-end product relationships and to totally exclude the possibility of rapid partial proteolysis of a normal precursor.
Unreduced immunoprecipitated secreted material from patient 11 is shown in Fig. 6 , lane 1. While both the unreduced intra-and extracellular material contain proteins of47,000 (Fig.  6 A) and 42,000 mol wt (Fig. 6 D) , the secretions also contain a 30,000-mol-wt (Fig. 6 E) molecule not present inside the cells. The cytoplasm contains molecules of 27,000 mol wt (Fig. 4 B) and 15,000 mol wt (Fig. 4 C) not seen extracellularly. Despite these differences in the unreduced precipitates, reduction ofboth yields the same two polypeptides of 27,000 and 15,000 mol wt, respectively (Fig. 6 , lanes 2 and 3, BR and CR). The larger represents the alkylated lambda monomer while the smaller is an incomplete lambda chain. Hence, all the intracellular and extracellular lambda-containing molecules represent disulfidelinked homo or heteropolymers ofthese two peptides, i.e., X2 at 47,000 mol wt, XXF at 42,000 mol wt, and (XF)2 at 30,000 mol wt. Since only dimers are found extracellularly and monomers are readily detectable inside the cell, it is likely that the free SH groups are either blocked by cellular SH donors or that intracellular conditions provide a reducing environment.
Since the precipitations in all the experiments reported here free L-chain secreted by the cells during the labeling period was small. A number of reports have suggested that some AL patients may respond to drugs that are effective in the therapy of multiple myeloma (18, 20, 21) . We have studied several who have been treated with such regimens. The results of one such analysis are shown in Fig. 9 . Before therapy, (Fig. 9 A) the marrow cells of the patient (patient 1 1) (see above) synthesized and secreted a normal sized lambda chain, its dimer, a lambda fragment, and its dimer. Time-course studies suggested that the fragment was not the result of intracellular proteolysis (Figs. 4 and 5) . In addition, the marrow cell population produced virtually no free kappa chains and only small amounts of H2L2-containing kappa chains.
Cells obtained from the same patient 9 mo later, after monthly courses ofcytotoxic agents and prednisone, were labeled and analyzed in a similar fashion. Fig. 9 B shows that the marrow cells no longer synthesized free lambda chain or fragments. The marrow now synthesized both kappa-and lambda-containing H2L2 in a ratio of approximately 3:2, hence approximating the pattern seen when normal bone marrow cells are studied using these techniques (Fig. 1) Fig. 7 shows conventional electrophoretic and immunoelectrophoretic analyses from one such patient that reveal no monoclonal Igs or L-chains. Analysis of cytoplasm revealed monoclonal kappa production (Fig. 8) . Bone marrow cells from patients without myeloma or AL disease synthesize free L-chains (Fig. 1) Figure 7 . Serum and 400-fold concentrated urine from patient 10 were subjected to cellulose acetate electrophoresis with immunofixation as described. No monoclonal proteins were noted. Hypogammaglobulinemia is evident. The electropherograms were developed with anti-Ig heavy and L-chain and anti-transferrin sera. In this system discrete Ig L-chain fragments derived from V-regions run at the extreme cathodal portion of the gamma region. Constant region fragments tend to run anodally.
concentrated urine specimens from normals and individuals with polyclonal hyperglobulinemia (22). We have studied a small number of such individuals and demonstrated the presence of L-chain monomers and dimers ofboth kappa and lambda classes in a ratio of -3:2 with no immunologically precipitable species smaller than the size of intact L-chains detectable. Most AL patients synthesize lambda proteins so that reversal ofthe kappa/ lambda ratio in the L-chains synthesized in short-term tissue culture is probably significant. Further, normal Ig synthesis is usually suppressed in these patients. Hence, the use of the bio- synthetic assay as an analytic tool increased the demonstrable presence of monoclonal L-chains in AL disease to 100%. Tissue deposition ofthese molecules in the absence ofreadily detectable serum or urine proteins may reflect relatively low synthetic and secretory rates coupled with the putative high affinity of the Lchains or their fragments for tissue sites (23) .
We have previously reported changes in the spectrum of Igrelated molecules in a patient treated with a protocol similar to that used in the therapy ofmultiple myeloma (18) . In that patient, clinical improvement was associated with a change in Ig synthesis. Patient 11 demonstrates a similar result. The patient's urine contained only trace amounts of a monoclonal lambda Lchain. Gingival biopsy revealed amyloid with lambda determinants demonstrable immunohistochemically (17a). Biosynthetic studies at the time of diagnosis showed both qualitative and quantitative L-chain abnormalities. Repeat analyses 9 mo later, after monthly courses of melphalan and prednisone, showed an essentially normal biosynthetic pattern with no excess L-chain production and H2L2 synthesis with a kappa/lambda ratio of roughly 3:2. Hence, therapy was accompanied by normalization in the pattern of Ig biosynthesis both quantitatively and qualitatively, suggesting elimination of the monoclonal plasma cell population responsible for synthesis. Fig. 8 shows similar analyses in a patient who showed no clinical response. In this case the difference in the amount of L-chain monomer synthesized may represent an effect of therapy or a result of variation in the labeling protocol. These data demonstrate that biosynthetic analyses can be utilized to monitor patients' responses to therapy.
Scattered case reports suggest that some patients with AL disease have increased survival when treated with melphalan and prednisone (18, 20, 21 Tables I and II reveals no association between the clinical picture of neoplasia, i.e., multiple myeloma, and the presence of small molecules bearing light L-chain antigenic determinants.
Alternatively, the fragments might represent proteins coded by different L-chain genes. That this appears to be unlikely is indicated by structural studies of deposited proteins that seem to demonstrate identical amino-termini in those fragments that have been analyzed. However, this is still a possibility. The fragments may represent the products oftranscripts from a normally rearranged gene that contains abnormal termination signals. These would result in normal NH2 termini but aberrant COOH termini (28) . It is also possible that the fragments that we are detecting are the protein products of COOH region transcripts containing little or no V-sequence and are irrelevant to the tissue deposition of Ig that marks these patients. In murine tumors of the B and T lineages a number of instances have now been reported in which aberrant peptides have been synthesized using templates that represent abnormal transcripts either from the same chromosome coding for the major cell product or from the other, incorrectly rearranged, chromosome (29) .
Over the years a number ofreports have appeared describing human L-chain proteins that vary in size from the prototype structures. Molecules that are apparently larger than normal have been analyzed, but not in sufficient detail to establish what they represent vis-a-vis normal L-chain structure. A few have been found to be normal size peptides that are relatively heavily glycosylated. It has been assumed, but not established, that the others are extended peptides (30). The protein synthesized by patient 6 may represent such a molecule.
More relevant to the present work are the descriptions of smaller polypeptides bearing L-chain determinants that are antigenically deficient relative to normal L-chains ofthe same class (31, 32) . Most of these have been isolated from the urine of patients with multiple myeloma, with at least one investigator finding these fiagments in about one-third of the urinary Lchain preparations examined. Their frequent occurrence coupled with their absence from serum have suggested that they arise through the action of serum or urine proteases. It has not been noted whether the fragments have been isolated from individuals with amyloidosis.
We have not seen fragments in labeling experiments in cells obtained from polyclonal hyperglobulinemic marrows (Fig. 1 ) and patients with myeloma or macroglobulinemia. We have had no difficulty, as have others, in identifying fragments in human heavy chain diseases, and monoclonal Ig deposition disease, a condition in which intact Ig chains or related polypeptides are deposited in tissues, although without the fibril formation that is the morphologic sine qua non of amyloidosis (33, 34) . It is possible that analysis of synthesis in AL and monoclonal Ig deposition disease patients will provide further insights into the regulation of expression of human Ig genes. At the moment, however, it appears that the analysis ofthe molecules synthesized by their bone marrow cells is clinically useful both for diagnostic purposes and for monitoring therapeutic intervention.
